ClinicalTrials.gg
Not yet recruitingNCT06934486Updated Feb 10, 2026

Observational Study of TissuePatch SF in Prevention of Air Leaks Following Lung Resection

An observational study in Post-operative Air Leaks, sponsored by C. R. Bard. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by C. R. Bard (part of Becton, Dickinson and Company) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Post-market, observational study to assess effectiveness of TissuePatch SF in managing/preventing air leaks after lung resection.

Read the detailed description

Post-market study conducted to assess the continuing effectiveness and safety of TissuePatch SF when used as an adjunct to standard suture/staple closure of clinically significant (Macchiarini Grade ≥1) intra-operative visceral pleural air leaks incurred during lobectomy and segmentectomy (open or minimally invasive), including those performed as video-assisted thoracic surgery (VATS), in adults.

02

Conditions studied

  • Post-operative Air Leaks
03

In context

Lead sponsor

C. R. Bard is the lead sponsor of 117 studies on the registry; 6 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 13 (76%) have results posted.

First submitted after C. R. Bard became part of Becton, Dickinson and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing lung resection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is ≥18 and \<80 years of age
  2. Undergoing planned (not emergent) video-assisted thoracic surgery pulmonary resection
  3. Understands and is willing to comply with all study related procedures
  4. Has provided signed

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating or, if of , are unwilling to use for 6-months following surgery
  2. Has severe congestive heart failure, pulmonary or renal failure, serious haematological disorder or significant liver disease
  3. Has previously undergone a pneumonectomy
  4. Has a bronchial fistula
  5. Has or is suspected of having an active infection at or near the planned surgical site
  6. Has a known allergy or sensitization to TissuePatch SF or its constituent components
  7. In the investigator's opinion, has a of less than 12 months
  8. Has, in the investigator's opinion, any disease or condition, physical or psychological, that could interfere with the evaluation of TissuePatch SF or compliance with study procedures

Intra-Operative Exclusion Criteria:

  1. >3 identified air leaks
  2. No air leaks Macchiarini Grade ≥1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with intra-operative air leak detected during lung resection

    Device: TissuePatch Sealant Film

Interventions

  • DeviceTissuePatch Sealant Film

    Sealant film

06

What researchers measure

Primary outcomes

  1. Intra-operative air leaks

    Air leaks successfully sealed or reduced as assessed by a submersion air leak test

    Time frame: Prior to the completion of surgery

Secondary outcomes

  1. Overall device safety

    Incidence of serious adverse events

    Time frame: 3-months post surgery

  2. Overall device safety

    Adverse events probably or causally related to the study device

    Time frame: 6-months post-surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Feb 2028, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 18, 2025
StartEst.
Jul 1, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06934486
Lead sponsor
C. R. Bard
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Jul 1, 2026 (estimated)
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Director of Clinical Affairs
Contact
jaime.ritter@bd.com
4043271221

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion